Psychometric evaluation of the hypoparathyroidism symptom diary using data from two clinical trials

Lauren Nelson(RTI Health Solutions), Olulade Ayodele(Takeda (United States)), Steven Ing(The Ohio State University Wexner Medical Center), Susan Martin(RTI Health Solutions), Mishaela R. Rubin(Columbia University Irving Medical Center), Rohini Sen(AbbVie (United States)), Jia Ma
Endocrine Abstracts
May 7, 2022
10.1530/endoabs.81.p33
Cited by 0

Related Papers

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
|British Journal of Dermatology|2019|384
Characteristics and healthcare costs of patients with fibromyalgia syndrome
|International Journal of Clinical Practice|2007|335
Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial
|The Journal of Clinical Endocrinology & Metabolism|2004|283
Assessing test–retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula
|Quality of Life Research|2018|247
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
|Calcified Tissue International|2019|160